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resumo 
 
 
A doença de Alzheimer (DA) é uma doença neurodegenerativa caracterizada 
pela presença de duas características histopatológicas: as placas senis na 
matriz extracelular compostas por Beta-amilóide (Abeta) e as tranças 
neurofibrilhares intracelulares contendo proteína tau hiperfosforilada. Assim, o 
Abeta e a proteína tau são importantes moléculas associadas à DA e 
evidências sugerem que o Abeta possa mediar a hiperfosforilação da tau 
levando á disrupção da rede neuronal e consequentemente ao processo de 
neurodegeneração. No presente estudo, em culturas primárias neuronais de 
córtex e hipocampo de rato, verificou-se que a exposição a Abeta1-42 agregado 
por longos períodos diminui a fosforilação da tau nos resíduos Ser202 e 
Thr205 e, em contraste, aumenta a fosforilação no resíduo Ser262.  
Pensa-se que a hiperfosforilação da tau na DA pode estar relacionada com 
alterações nas vias de sinalização celular envolvidas no processo de 
fosforilação da tau, tais como alterações na regulação das cinases e das 
fosfatases. Deste modo, é também de extrema importância determinar as 
cinases e fosfatases envolvidas neste processo. Por tratamento de neurónios 
corticais com diferentes concentrações de ácido ocadéico (AO), um inibidor 
das fosfatases, verificamos o envolvimento da PP1 na desfosforilação da tau 
nos resíduos Ser202 e Thr205, bem como o envolvimento da PP1 e PP2A na 
desfosforilação do resíduo Ser262.  
Um outro aspecto importante do metabolismo da tau são as proteínas de 
ligação, e actualmente já foram descritas várias proteínas que interagem com 
a tau in vitro e in vivo. O interactoma da tau é regulado pela sua fosforilação e 
portanto é crucial estabelecer uma relação entre a tau normal e a tau 
patológica hiperfosforilada no que diz respeito às proteínas de ligação. Por co-
imunoprecipitação de neurónios corticais pretendemos identificar proteínas de 
ligação à tau e especificamente à tau fosforilada, e ainda avaliar o efeito do 
Abeta neste interactoma. O interactoma da tau dependente da fosforilação e 
do Abeta é de particular relevância para a compreensão da DA.  
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abstract 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the 
presence of two histopathological hallmarks: the extracellular amyloid plaques 
(APs) composed of beta-amyloid protein (Abeta) and intracellular neurofibrillary 
tangles (NFTs), containing hyperphosphorylated tau protein. Therefore, Abeta 
and tau are important molecules associated with AD and evidence suggests 
that Abeta may initiate the hyperphosphorylation of tau, which by disrupting 
neuronal network leads to the process of neurodegeneration. In the present 
study, using rat primary cortical and hippocampal neuronal cultures, it was 
shown that exposure to aggregated Abeta1-42 for prolonged periods decreased 
tau phosphorylation at Ser202 and Thr205 residue, but in contrast increased at 
Ser262 residue. Tau hyperphosphorylation in AD may be related to alterations 
in signal transduction pathways involving tau phosphorylation, such as an 
imbalance in the regulation of protein kinases (PKs) and protein phosphatases 
(PPs). Thus it is also important to determine which specific PKs and PPs are 
involved in this process. We observed the involvement of PP1 in the 
dephosphorylation of tau at Ser202 and Thr205, and the involvement of PP1 
and PP2A at the Ser262 residue. 
An important aspect of tau metabolism are its binding proteins, and to date 
many such proteins have already been described both in vitro and in vivo. The 
interactome of tau is shaped by its phosphorylation and so is crucial to map the 
crosstalk between normal and pathologically hyperphosphorylated tau. By co-
immunoprecipitation we intend to identify proteins that interact with tau and 
more specifically with phosphorylated tau (p-Tau). Furthermore the effect of 
Abeta on this interactome should be forthcoming, which is relevant for AD tau 
pathology.  
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Abbreviations 
 
Abeta Amyloid peptide 
AD Alzheimer´s disease 
ADAM A Disintegrin And Metalloproteinase 
AICD Amyloid precursor protein intracellular domain 
AP Amyloid plaques  
APS Ammonium persulfate 
Aph1 Anterior pharynx-defective 1 
APLP1 APP like protein 1 
APLP2 APP like protein 2 
ApoE Apolipoprotein E 
APP Alzheimer´s amyloid precursor protein 
ATP Adenosine triphosphate 
BACE Beta-site APP-cleaving enzyme 
BCA Bicinchoninic acid 
BSA Bovine serum albumine 
CaMPKII Ca2+/Calmodulin-dependent protein kinase II 
Cdc2 Cyclin-dependent protein kinase 2 
Cdk5 Cyclin-dependent protein kinase 5 
CSF Cerebrospinal fluid 
CNS Central nervous system 
CT Computarized tomography 
C-terminal Carboxyl-terminal 
CTF Carboxyl-terminal fragment 
DTT Dithiothreitol 
E Exon 
EC Extracellular domain 
ECL Enhanced chemiluminescence 
EDTA Ethylenediamine tetraacetic acid 
ER Endoplasmic reticulum 
FAD Familial Alzheimer´s disease 
FBS Fetal bovine serum 
Fc Fragment crystallizable 
GSK3 Glycogen synthase kinase 3 
HBSS Hank´s balanced salt solution 
HSP70 Heat shock protein 70 
HSP90 Heat shock protein 90 
IB Immunoblotting 
IC Intracellular domain 
IC50 50% inhibition concentration  
IgG Immunoglobulin G 
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IP Immunoprecipitation 
JIP1b JNK-interacting protein 1b 
JNK Jun N-terminal kinase 
KLC Kinesin light chain 
KPI Kunitz-type serine protease inhibitor 
LB Loading buffer 
LC-MS/MS Liquid chromatography-mass spectrometry 
LGB Lower gel buffer 
MAP Microtubule associated proteins 
MAPK Mitogen activated protein kinases 
MAPT Microtubule Associated Protein Tau 
MARK Microtubule-affinity regulating kinase 
MOPS 3-(N-morpholino)propanesulfonic acid 
MRI Magnetic resonance imaging 
NFT Neurofibrillary tangles 
NMDA N-Methyl-D-aspartic acid 
NPDPK Non - Proline directed protein kinases 
NSAID Nonsteroidal anti-inflammatory drug 
N-terminal Amino-terminal 
OA Okadaic acid 
ON Overnight 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline - tween 
PDPK Proline directed protein kinases 
PEN-2  Presenilin enhancer 2 
PET Positron emission tomography 
PHF Paired helical filaments 
Pin1 Protein interacting with NIMA 
PK Protein kinase 
PKA Cyclic-AMP-dependent kinase 
PKC Protein kinase C 
PLC Phospholipase C 
PP Protein phosphatase 
PSEN1 Presenilin 1 
PSEN2  Presenilin 2 
p-tau Phosphorylated tau 
RIPA Radio-Immunoprecipitation Assay 
RNA Ribonucleic acid 
RT Room temperature 
SAP Stress-activated protein 
sAPP Secreted APP 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE Standard error 
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Ser Serine 
SH3 SRC homology 
TBS Tris Buffered Saline 
TBS_T Tris Buffered Saline - tween 
TGN Trans-Golgi network 
Thr Threonine 
TRIS  Tris(hydroxymethyl)aminomethane 
Tyr Tyrosine 
TM Transmembrane domain  
UGB Upper gel buffer 
WR Working reagent 
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1.1.  Alzheimer ’s disease (AD) 
 
Alzheimer´s disease (AD) is a neurodegenerative disorder first described in 
1906 by Dr. Alois Alzheimer5,9. AD is the most common form of dementia among the 
elderly, and currently affects about 18 million people worldwide, 7.3 million in 
Europe and about 90.000 people in Portugal2-4,10-11. Dementia is the loss of cognitive 
functions such as thinking, remembering and reasoning, that interfere with a person´s 
daily life and activities2,12.   AD is characterized by memory, language, learning and 
other cognitive impairments, severe enough to interfere with social, occupational and 
personal functions3-5,12-14. Besides this cognitive decline, behavioral, emotional and 
psychiatric symptoms are also frequent in AD14.  
 
 
1.1.1.  Epidemiology and Genetics   
 
The most prevalent forms of AD are sporadic, with the symptoms beginning 
after 65 years of age, and are called late-onset AD. But there is a small percentage of 
cases (less than 5%) with an early onset (30-60 years), generally inherited in an 
autosomal-dominant manner – the familial AD (FAD). There are some risk factors for 
developing sporadic AD (late-onset AD) such as advancing age, the presence of 
certain alleles of the Apolipoprotein E gene (ApoE), gender, level of education and 
head trauma. The single most important risk factor is age, since the rate of occurrence 
of the disease doubles approximately every five years after the age of 654,14-15. 
Apolipoprotein E gene (ApoE) is localized to chromosome 19, encodes a glycoprotein 
involved in cholesterol transport and alters the risk of developing AD but does not 
cause it. The gene codifying this protein has three possible alleles: ε2, ε3 and ε4. The 
ε3 is the most common allele in the general population and ε2 the less common. The 
ε4 allele is connected with an increased risk of developing AD. The mechanism 
through which this allele increases the risk is unknown but it appears that the ε4 
allele along with other proteins may influence Abeta metabolism and its aggregation 
in the Central nervous system (CNS)16-18. 
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Additionally mutations in three different genes: presenilin-1 gene (PSEN1) 
located on chromosome 14, presenilin-2 gene (PSEN2) located on chromosome 1 and 
amyloid precursor protein gene (APP) on chromosome 21, are known to cause 90% 
of the FAD14-15,18. The APP gene encodes a transmembrane glycoprotein abundant in 
the nervous system that is proteolytically cleaved to produce Abeta. As this gene is 
localized to chromosome 21, this explains the observation that patients with Trisomy 
21, which possess an extra copy of the APP gene, develop early in life (40 years) the 
neuropathological features associated with AD (like Abeta deposition). Studies have 
allowed to conclude that most of the APP mutations alter the proteolytic processing 
of APP resulting in increased Abeta production16-18. The PSEN1 and PSEN2 genes 
encode two highly homologous transmembrane proteins whose normal functions are 
not yet known. However the products from proteolytic cleavage of these proteins are 
known to be essential to gamma-secretase complex formation. The majority of 
mutations in PSEN1 and PSEN2 are missense and increase the activity of gamma-
secretase and consequently Abeta production. From all early-onset AD cases 50% are 
linked to the PSEN1 gene and only a few cases are associated to the PSEN2 gene16-17 
 
1.1.2. Histopathological Hallmarks 
 
In AD there is neuronal and synaptic loss associated with two 
histopathological hallmarks: the extracellular amyloid plaques (AP, Fig. 1) and 
intracellular neurofibrillary tangles (NFTs, Fig. 1), in distinct brain areas including the 
neocortex and hippocampus 15,19.  
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Figure 1 – Two histopathological hallmarks of AD: Amyloid plaques (AP) and Neurofibrillary tangles 
(NFTs)20. 
 
 
Amyloid plaques are extracellular insoluble deposits of a protein fragment, the 
beta-amyloid (Abeta) generated by proteolytic cleavage of the amyloid precursor 
protein (APP), surrounded by dystrophic neurites. The Abeta peptide is a 
physiological soluble cellular metabolite that comprises two predominant forms, the 
Abeta1-40 and the Abeta1-42 which differ in their C-terminal15. The Abeta1-40 is the most 
predominant and presumably is not neurotoxic while the Abeta1-42 is less prevalent, 
more hydrophobic and more toxic. The Abeta1-42, is also proportionally increased in 
patients with AD and has a major propensity to aggregate and to form oligomers and 
fibrils that ultimately generate amyloid plaques6. The steady state level of Abeta is 
controlled by its production, degradation and clearance. In AD it is proposed that the 
cause of Abeta accumulation is a defect that leads to its over-production or decreased 
clearance4. Although, actually, it remains unclear what triggers these alterations in 
APP and Abeta metabolism causing this increased production and aggregation of 
Abeta peptide. However it is known that Abeta accumulation and aggregation results 
in organelle and membrane damage, which in turn leads to the disruption of cellular 
processes and also oxidative stress, inflammation and cell death6.  
The NFTs are intracellular aggregates composed of bundles of paired helical 
filaments (PHF) whose major protein component is the microtubule-associated tau 
protein. In PHF the tau protein is abnormally hyperphosphorylated and 
aggregated14,18,21-22 and so has a reduced ability to bind to microtubules and to 
promote their assembly. As a consequence the axonal cytoskeleton is disturbed, 
axonal transport disrupted and finally neuronal viability compromised23. For 
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example, synapses are very vulnerable to these perturbations in the axonal transport 
system since it causes dysfunction in neurotransmission and signal propagation 
leading to synaptic degeneration.24 Thus, the number of NFT are positively correlated 
with the degree of AD, and the same does not occur with amyloid plaques24. 
 
 
1.1.3. Diagnosis and Treatment  
 
Currently, the diagnosis and treatment of AD is limited and insufficient. As 
such definitive diagnosis of AD is still only possible after death, with an examination 
and pathological analysis of brain tissue during an autopsy, where the presence of the 
senile plaques and neurofibrillary tangles is confirmed. However, there are many 
current tools that are used to diagnose AD patients or even to exclude this pathology. 
These tools included detailed patient medical history, information obtained from 
family members, physical and neurological examinations, laboratory tests, 
neuropsychological tests to measure, for example language and memory skills and a 
variety of other approaches, including neuroimaging studies such as computerized 
tomography (CT), magnetic resonance imaging (MRI) and positron emission 
tomography (PET). The neuroimaging techniques are of great help since they provide 
regional structural and functional details of the brain, as well as assist in the 
identification of the biochemical profile of brain dysfunction25. Although there are 
significant advances in these neuroimaging techniques, the use and identification of 
novel AD biomarkers is necessary since they give more direct and convenient 
information to detect the preclinical stages of AD, as well as assisting in the study of 
disease progression25-26. The most important potential sources of AD biomarkers are 
cerebrospinal fluid (CSF), plasma and urine25. Currently the quantification of Abeta 
and tau, both total and phosphorylated tau, in the CSF is the more appropriate to 
detect early AD patients26. An early diagnosis of AD is beneficial, as it facilitates the 
efficient treatment with new generation of disease modifying drugs12.  
Regarding the treatment for AD, it is a complex disease and no single 
treatment is likely to prevent or cure it. Thus current treatments focus on helping 
patients maintain mental function, managing behavioral symptoms and delaying the 
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disease14. Actually the therapies for AD can be based in symptomatic approaches or 
based in neuroprotective approaches. Therefore there are five major categories of 
drugs used in AD treatment: the acetylcholinesterase inhibitors, antiglutaminergic 
treatment, vitamins and antioxidants, anti-inflammatory drugs and pharmacological 
management of behavioral disturbances27. From these, the most successful AD drugs 
to date are the acetylcholinesterase inhibitors since in AD there is a deficiency in 
cholinergic neurotransmission that plays a major role in the expression of cognitive 
functional and behavioral symptoms of AD. Thus acetylcholinesterase inhibitors act 
by stopping or slowing down the action of acetylcholinesterase, a catabolic enzyme 
that breaks down acetylcholine, the neurotransmitter involved in memory formation, 
prolonging its action at cholinergic synapses14,27-28. The antiglutaminergic treatment, 
for example the memantine, is another therapeutic approach, but in this case it blocks 
glutamatergic neurotransmission, since it is an uncompetitive antagonist of NMDA 
receptors avoiding its hyperstimulation which causes neuronal dysfunction and 
death14,27. Evidence that free radicals may accumulate in AD brains, due to the 
existence of oxidative stress, has led to interest in the use of antioxidants such as 
vitamin E. Nonsteroidal anti-inflammatory drugs (NSAIDs) may have a protective role 
against the development of AD but this effect does not extend once AD is 
established27. Concerning the management of behavioral disturbances it can be 
achieved by using nonpharmacological (music, light exercise, relaxation exercise) or 
pharmacological approaches using anxiolytic, antidepressive or antipsychotic drugs. 
The future of therapies in AD will be based on the understanding of AD 
pathophysiology and could be achieved with anti-amyloid therapies that are being 
studied. The development of these therapies has two main approaches: reduce the 
production of Abeta that can be achieved by inhibiting beta- and gamma-secretase, or 
increase its clearance by anti-amyloid immunotherapy. The main goal of these new 
approaches is to modify the progression of the disease; these are called disease-
modifying drugs14,27. 
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1.2. Alzheimer´s amyloid precursor protein (APP) 
 
APP is a ubiquitously expressed membrane-spanning glycoprotein with a large 
N-terminal extracellular domain (EC) and a small cytoplasmic domain (IC) 21,29. It is a 
member of a conserved family of type I membrane proteins including APP like 
protein 1 (APLP1) and APP like protein 2 (APLP2) in mammals. While the APP and 
APLP2 are ubiquitous but with highly expression in neurons, the APLP1 is brain-
specific29-30. APP is encoded by a gene localized on the mid-portion of the long arm of 
human chromosome 21 (21q21) and contains 18 exons30-31.  Alternative splicing of 
the exons 7, 8 and 15 generates eight APP isoforms that range from 365-770 amino 
acids. The most abundant APP isoforms are APP695, APP751 and APP770 (Fig. 2)15,32-33. 
APP751 and APP770 are largely expressed by non-neuronal cells and contain a domain 
homologous to the Kunitz-type serine protease inhibitor (KPI), encoded by exon 7, 
whereas the APP695 is expressed at higher levels in neurons and does not have the KPI 
domain30-31,34. KPI-containing APP isoforms are thought to be more amyloidogenic 
and their levels increase in the brains of AD patients15. However the cause and the 
functional significance for this tissue-specific isoforms is still not fully understood. 
 
 
 
Figure 2 – Schematic representation of the three major APP isoforms in mammalian tissues.  Numbers and 
vertical lines indicate the corresponding exons. The most abundant neuronal isoform, comprising 695 amino 
acids, is APP695. APP751 and APP770 are alternatively spliced isoforms that differ from APP695 in the expression of 
exons 7 and 8, as shown. The sequences encoded by the APP gene exons are indicated approximately to scale. The 
solid pink region represents the Abeta peptide region, whose sequence is divided between exons 16 and 17. 
Adapted from Cruz e Silva and Cruz e Silva, 2003. 
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In neuronal and non-neuronal cells, APP is generated in the endoplasmic 
reticulum (ER) and is known to be transported via the secretory pathway reaching 
cell surface. During its transit from the ER to the plasma membrane, APP undergoes 
post-translational modifications that include N- and O- glycosylation and tyrosine 
sulfation30,33. Therefore mature APP is located in compartments from the trans-Golgi 
to the plasma membrane, being that, only a small fraction is present at the plasma 
membrane. At the cell surface, APP can be cleaved or rapidly internalized via 
endocytosis to be recycled back to the membrane, retrogradely delivered to the trans-
Golgi-network (TGN) or incorporated into secondary endosomes. The majority of 
mature APP is proteolytically cleaved either via the alpha-secretase or beta-secretase 
pathway. It is thought that this proteolytic processing occurs through the secretory 
pathway, on the plasma membrane and/or in the endocytic cycle 30,35-36. Moreover, in 
neurons, APP is rapidly and anterogradely transported along peripheral and central 
axons36. 
Another important aspect is the fact that the trafficking, metabolism and even the 
functions of APP are regulated through interactions with several cytoplasmic 
proteins, for example, the relatively well analyzed Fe65, X11 and X11L,  JIP1b (JNK-
interacting protein 1) and KLC (kinesin light chain) proteins15,37 . All these proteins 
bind to the APP intracellular domain (AICD) at specific binding domains. 
 
1.2.1. APP Proteolytic processing   
 
APP can be cleaved by two major proteolytic processing pathways: the beta-
secretase and alpha-secretase pathway, also called amyloidogenic and non-
amyloidogenic, respectively. In the beta-secretase pathway the APP is first cleaved by 
the beta-secretase, releasing the ectodomain (sAPPbeta) while a C-terminal fragment 
with 99 amino acids (C99 or beta-CTF) remains membrane bound. Then C99 is 
cleaved by the gamma-secretase complex to produce Abeta peptide and the AICD. 
Alternatively, in the alpha-secretase pathway, alpha-secretase primarily cleaves APP 
releasing the ectodomain (sAPPalpha) and a membrane bound C-terminal fragment 
with 83 amino acids (C83 or alpha-CTF), which then is also cleaved by gamma-
secretase into p3 peptide and the AICD (Fig. 3)15,34,36. The majority of APP is 
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processed by the alpha-secretase pathway and so there is a balance between these 
two proteolytic pathways21. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Proteolytic processing of APP30. EC: extracellular domain; TM: transmembrane domain; IC: 
intracellular domain. The scheme is not to scale. 
 
Thus, there are three proteases involved in the cleavages of APP: the alpha-, beta- 
and gamma-secretases. The candidates for the alpha-secretase activity are members 
of the ADAM family of desintegrin and metalloproteases. BACE (beta-site APP-
cleaving enzyme) is a type I transmembrane aspartic protease, has two homologues, 
BACE1 and BACE2 that are the major beta-secretase in neurons. The gamma-
secretase is a multimeric complex with proteolytic activity formed at least by four 
proteins: PSEN1 or PSEN2, Nicastrin, PEN-2 and Aph136-37. 
 
 
 
 
 
 
Abeta dependent tau phosphorylation 
22 
 
1.2.2. APP phosphorylation  
 
Protein phosphorylation is an important cellular regulatory mechanism that is 
increased in AD. APP can be phosphorylated at multiple sites in both extracellular and 
intracellular domains. In the intracellular domains 8 putative phosphorylation 
residues are described: Tyr653, Thr654, Ser655, Thr668, Ser675, Tyr682, Thr686 
and Tyr68729,34,38-39. Since these residues are located in specific protein interacting 
sites its phosphorylation may interfere with protein binding and thus interfere with 
APP and AICD function.29 Previous studies point to an important role for the Thr668 
and Tyr682. The phosphorylation of both these residues is increased in AD brains: 
the Tyr682 is important for APP interactions with the cytosolic proteins and can 
promote or abolish them; the Thr668 phosphorylation allows Pin1 (a prolyl 
isomerase) binding and reduces Fe65 binding to APP and thus it alters APP 
processing and Abeta production40. In the APP ectodomain, phosphorylation at 
Ser198 and Ser206 residues are present, and occurs in a post-Golgi secretory 
compartment and at the cell surface.41 All of these APP phosphorylation sites are 
represented in Fig. 4.  
 
 
 
Figure 4 – Schematic representation of the phosphorylation residues present in the APP695 isoform 
protein: the two phosphorylated Ser residues present in the APP ectodomain, and the eight putative 
phosphorylated residues in the APP intracellular domain. EC: extracellular domain; TM: transmembrane domain; 
IC: intracellular domain29,41. 
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1.2.3. APP and APP fragments functions 
 
The precise roles of APP are unknown, although the overall structure of the 
protein suggests a role as a receptor or growth factor5. However some studies 
describe more putative roles for APP and its fragments in development, cell growth, 
intercellular communication, signal transduction, nuclear signaling and structural and 
functional plasticity29-30,42. Table 1 summarizes some of these putative roles for APP 
and its fragments that are produced during APP metabolism. 
 
 
Table 1 - APP and APP fragments (sAPP, Abeta and AICD) putative functions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
APP sAPP Abeta AICD 
- membrane       
receptor1-2 
- cell adhesion1-2 
- stimulation of 
neurite outgrowth1 
- synaptogenesis1,3 
- promotion of cell 
survival2 
-neuroprotection2,8 
-axonal transport3 
- promotion of 
neurite outgrowth1-2 
- synaptogenesis1 
- synaptic plasticity5 
- modulation of 
neuronal excitability 
and axon growth1 
- neuronal 
activation1 
- neuroprotection2 
- promotion of 
neuronal survival2 
-regulates calcium 
homeostasis3 
 
Physiological 
concentrations: 
- promotion of 
neurite outgrowth2 
- synapse function4 
- homeostatic 
plasticity3 
- neuronal survival4 
-cholesterol 
homeostasis3 
 
 
- gene 
transcription3 
- synaptic function3 
- synapse 
remodeling7 
Pathological 
concentrations: 
- neurotoxic1,6 
- synaptic 
dysfunction1 
- negatively affects 
neuronal viability1 
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1.3. Microtubule-associated tau protein 
 
 
Tau protein belongs to the microtubule-associated protein (MAP) family and 
was first isolated in 1975 as a protein that co-purifies with tubulin and has the ability 
to promote microtubule assembly in vitro24,43.  Tau is mainly a neuronal protein, 
although it can be expressed in non-neuronal cells43. The human tau gene, MAPT, is 
located on the long arm of chromosome 17 at band position 17q21 where it occupies 
over 100 kb 43-44.  The tau primary transcript contains 16 exons but three of them 
(exons 4A, 6 and 8) are never present in any mRNA of the human brain (Fig. 5)44. 
Exon 1 is part of the promoter and is transcribed but not translated, as is the case for 
exon 14. Exons 1, 4, 5, 7, 9, 11, 12 and 13 are constitutive, but exons 2, 3 and 10 are 
alternatively spliced, and exon 3 never appears in the absence of exon 2 43-44. 
Therefore, the transcript produced by alternative splicing of these three exons yields 
six different mRNA species that are then translated in six different isoforms of tau 
which range from 352 to 441 amino acids (Fig. 5) 22,43.  
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Figure 5 – Schematic representation of the human tau gene, mRNA and different protein isoforms24. The 
human tau gene is located over 100kb on the long arm of chromosome 17 at position 17q21. It contains 16 exons; 
exon -1 is a part of the promoter. The tau primary transcript contains 13 exons since exons 4A, 6 and 8 are not 
transcribed in human. Exons -1 and 14 are transcribed but not translated. Exons 1, 4, 5 ,7, 9, 11, 12, 13 are 
constitutive, and exons 2, 3 and 10 are alternatively spliced, giving rise to six different mRNAs, translated in six 
different tau isoforms. These isoforms differ by the absence or presence of one or two 29 amino acids inserts 
encoded by exon 2 and 3 in the amino-terminal part, in combination with either three (R1, R3 and R4) or four (R1, 
R2, R3 and R4) repeat-regions in the carboxyl-terminal part.  
 
The isoforms differ by the absence or presence of one or two acidic inserts 
(0N, 1N or 2N, respectively) at the amino-terminal (N-terminal) part of the molecule 
and whether they contain three or four repeats of a conserved tubulin binding motif 
(3R or 4R) at the carboxyl-terminal (C-terminal) region, and they can be designated 
as 3R0N, 3R1N, 3R2N, 4R0N, 4R1N and 4R2N44-48. Thus, the longest isoforms in the 
CNS has four repeats and two insert (441 residues), and the shortest isoforms has 
three repeats and no inserts (352 residues) (Fig. 5). The later isoform (3R0N), the 
smallest form of tau protein, is the only one expressed in fetal tissue while the six 
isoforms are expressed in adult brain46. It is thought that tau isoforms have specific 
physiological roles since they are differentially expressed during development43.  
Tau isoforms have two domains: the projection domain and the microtubule-
binding domain, that have been proposed to have distinct roles. The projection 
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domain contains the N-terminal two-thirds of the molecule and can be further 
subdivided into the acidic N-terminal region and a basic proline-rich region. The 
projection domain of tau determines spacings between axonal microtubules, interacts 
with other cytoskeletal proteins, for example, spectrin and actin filaments which 
allow microtubules to interconnect with other cytoskeletal components (Fig. 6). This 
domain may also allow interaction of tau with proteins associated with the neural 
plasma membrane and cytoplasmatic organelles, such as mitochondria, and there is 
some data indicating that tau proteins may interact with src-family non-receptor 
tyrosine kinases and phospholipase C-ɤ (PLC-ɤ), which suggests that tau may have a 
role on signal transduction pathways involving these two proteins. Moreover, the 
interaction of this domain with cytoskeletal and plasma membrane elements is only 
possible because this part of the molecule projects from the microtubule surface.  
 
 
 
 
Figure 6 – Summary of biological functions of tau associated with respective functional domain. E: exon; R: 
repeat domains. Adapted from Buée et.al, 2000. 
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The microtubule-binding domain contains the C-terminal one-third of the 
molecule and, likewise the projection domain, has been subdivided into the basic 
tubulin-binding domain region and the acidic C-terminal region (Fig. 6). As its name 
suggests, this domain is responsible for the binding of tau to microtubules and more 
specifically, tau binds microtubules through repetitive regions present in this domain.  
The repetitive regions are the repeat domains (R1, R2, R3 and R4) encoded by exons 
9, 10, 11 e 12 and with sequences of 31 or 32 residues very similar but not identical 
since they are composed by an 18 amino-acid sequence highly conserved and a less 
conserved sequence composed by 13 or 14 amino-acid sequence. The 18 amino-acid 
sequence is responsible for binding to microtubules, promoting microtubule 
polymerization and stabilization. For this reason tau isoforms with 4R (R1, R2, R3 
and R4) binds more efficiently to microtubules than the isoforms with 3R (R1, R2 and 
R3). Besides microtubule assembly recent data suggests that the microtubule-binding 
domain can also modulate the phosphorylation state of tau proteins since it can bind 
directly with the protein phosphatase 2A (PP2A) and in consequence microtubules 
can inhibit PP2A activity by competing for binding to tau at this domain 43-44,46,49. 
 
 
1.3.1. Posttranslational modifications of tau protein  
 
Like many other proteins that are implicated in human disease, tau protein is 
posttranslationally modified. Several modifications have been described for tau 
protein such as phosphorylation, glycosylation, ubiquitination, glycation, truncation 
and deamination. Of all posttranslational modifications the most important is 
phosphorylation because it is an important cellular regulatory mechanism.   
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1.3.1.1 Tau phosphorylation 
 
Tau is a phosphoprotein that possesses a large number of potential 
phosphorylation sites mainly serine, threonine and tyrosine residues45,49. On the 
longest brain tau isoform (441 amino-acids) there are 45 serine and 35 threonine 
putative phosphorylation sites, and at least 35 phosphorylation sites have already 
been described (Fig. 7)43. 
 
Figure 7 – Representation of phosphorylation sites already described on the longest brain tau isoform 
using phosphorylation-dependent monoclonal antibodies against tau, mass spectrometry and sequencing. 
All of these sites are localized outside microtubule-binding domains with the exception of Ser262, Ser285, Ser305, 
Ser324, Ser352 and Ser35643. E: exon; R: repeat domain. 
 
The level of tau phosphorylation is a dynamic process controlled by several 
protein kinases and protein phosphatases (summarized in table 2). Interestingly, tau 
phosphorylation is developmentally regulated as fetal isoforms are more 
phosphorylated during neurogenesis and synaptogenesis and then phosphorylation 
decreases during development due to phosphatases activation43.  
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Table 2- Protein kinases and protein phosphatases most probably involved in tau protein 
phosphorylation and dephosphorylation, respectively 13,43-44,47-50. 
Kinases 
 
Proline directed protein kinases (PDPK) 
 
 
Glycogen synthase 3 (GSK3)                                                                             
Mitogen activated protein kinase (MAPK)                                                        
Tau-tubulin kinase                                                                                                       
Cyclin-dependent Kinases (cdc2 and cdk5)                                                  
Stress-activated protein kinases (SAP) 
 
 
Non-proline directed protein kinases (NPDPK ) 
 
 
Microtubule-affinity regulating kinase  (MARK)                                        
Ca2+/calmodulin-dependent protein kinase II (CaMPKII)                                                                                                                     
Cyclic-AMP-dependent kinase (PKA)                                                 
Casein Kinase II                                                                                        
Protein kinase C (PKC) 
 
Phosphatases 
 
 
Protein phosphatase 1 
Protein phosphatase 2A 
Protein phosphatase 2B (calcineurin) 
 
 
 
The majority of the kinases involved in tau phosphorylation belong to the 
Proline-directed protein kinases (PDPK) which comprise glycogen synthase 3 (GSK3), 
mitogen activated protein kinase (MAPK), tau-tubulin kinase, cyclin-dependent 
kinases such as cdk2 and cdk5, and stress-activated kinases (SAP kinases). Another 
group named non-PDPK or NPDPK comprises microtubule-affinity regulating kinase 
(MARK), Ca2+/calmodulin-dependent protein kinase II (CaMPKII), cyclic-AMP-
dependent kinase (PKA), casein kinase II and protein kinase C (PKC)13,43,47-49. GSK3 is 
one of the protein kinases that has gained significant attention as a tau kinase and 
comprises the highly homologous proteins GSK-3α and GSK-3β46. GSK-3β is highly 
expressed in brain and associates with microtubules47. Some studies in which tau and 
GSK-3β are co-transfected into non-neuronal cells showed an increase in tau 
phosphorylation and impairment in the binding of tau to microtubules46,51-52. 
Interestingly, this kinase can phosphorylate numerous sites on tau protein, not all 
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having an impact on tau function51. Other important tau kinases are the MAPKs in 
which some of its members can phosphorylate tau: p42mapk, p44mapk, pk40erk2 and 
p493F12. It was shown in several studies that these MAPKs phosphorylate tau protein 
in cultured neurons mainly via activation of tyrosine kinase receptors and protein 
kinase cascades46. Cdk5 is a member of cyclin-dependent kinase family and its activity 
is highest in neurons due to selective expression of its regulator p35 in these cells51. 
This kinase induces phosphorylation of tau protein in vitro, maybe not directly but 
instead by regulating the kinases and phosphatases that act on tau47. The NPDPK 
cyclic-AMP-dependent kinase (PKA) is shown to phosphorylate tau in vivo47. Since 
many kinases are likely to be involved in tau phosphorylation one possibility is that 
tau might be primed by one kinase before subsequent phosphorylation by a second 
kinase that recognizes a nearby phosphorylated residue53. 
Regarding protein phosphatases (PP) several studies have shown that three 
major PPs: PP1, PP2A and PP2B (calcineurin), but not PP2C can dephosphorylate tau 
in vitro44,49-50. All of these PPs are present in the brain and are developmentally 
regulated43. The PP2A is the most probable phosphatase that acts on most 
phosphorylation sites and it is also associated with microtubules46,49-50,54. It was 
shown that, in cultured neurons treated with okadaic acid and calyculinA 
(phosphatase inhibitors) at concentrations sufficient to inhibit PP2A, 
phosphorylation of tau was increased54. Similar studies using PP2B inhibitors also 
suggest that PP2B is involved in the dephosphorylation of tau protein but at different 
sites of the PP2A43. PP1 involvement in tau phosphorylation was also demonstrated 
by inhibition of phosphatases in neuronal cell lines. Although, PP2C has been 
reported to dephosphorylate tau phosphorylated by PKA in vitro, these 
dephosphorylations did not affect PHF tau46. Table 3 summarizes the 
phosphorylation residues in human tau associated with its tau-directed protein 
kinases and phosphatases. 
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Table 3 – Tau-directed protein kinases and phosphatases and respective phosphorylation residues in 
human tau 44,46. In bold are the residues addressed in this study. 
 Residues on human tau 
Kinases  
GSK3β Ser46, Thr50, Thr181, Ser184, Ser195, Ser198, Ser199, Ser202, Thr205, 
Thr212, Thr217, Thr231, Ser235, Ser262, Ser356, Ser396, Thr403, 
Thr404 
GSK3α Ser199, Ser202, Thr212, Thr231, Ser235, Ser262, Ser324, Ser356, 
Ser396, Ser404 
Cdc2 Ser195, Ser202, Thr205, Thr231, Ser235, Ser396, Ser404 
Cdk5 Thr181, Ser195, Ser199, Ser202, Thr205, Thr212, Thr214, Thr217, 
Thr231, Ser235, Thr373, Ser396, Ser404 
MAPK Ser46, Ser199, Ser202, Ser235, Ser396, Ser404, Ser422 
PKA Ser214, Ser234, Ser262, Ser293, Ser324, Ser356, Ser409, Ser416 
PKC Thr123, Ser262, Ser324 
CaM Kinase II Thr135, Ser137, Thr212, Ser214, Ser262, Ser356, Ser409, Ser416 
Casein kinase II Ser396, Ser404 
Phosphatases  
PP1 Ser199, Ser202, Thr231, Ser396, Ser404 
PP2A Ser46, Thr231, Thr181, Ser199, Ser202,Thr205, Ser262, Ser396, Ser404 
 
 
1.3.2.1. Other posttranslational modifications of tau protein 
 
Glycosylation is an enzymatic process through which oligosaccharides are 
covalently attached to the side chain of polypeptides. There are two types of 
glycosylation according to the nature of glycosidic bonds: O-glycosylation and N-
glycosylation. In tau protein, both types have been reported, but O-glycosylation 
occurs in unmodified tau whereas N-glycosylation occurs in hyperphosphorylated 
tau. It was reported that the inhibition of protein phosphatases, which induces tau 
hyperphosphorylation, also decreased O-glycosylations49. Thus, later, a reciprocal 
relationship between the O-glycosylation and phosphorylation was established, in 
which O-glycosylation negatively regulates tau phosphorylation44.  
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Ubiquitination consists in the association of ubiquitin, a stress protein, with 
misfolded or damaged proteins to be degraded in an ATP-dependent manner. The tau 
protein can be ubiquitinated, however it has only been thus found when in NFTs. 
Despite the PHF-tau being highly ubiquitinated, it is not degraded and instead it is 
deposited as NFTs in AD brain44,49. 
In tau isolated from PHF the glycation was present which refers to a non-
enzymatic linkage of a reducing sugar to a polypeptide. This glycation might be 
involved in the insolubility/aggregation of PHFs into NFTs since a cross-linking 
reaction leading to the formation of insoluble aggregates of proteins is often 
described as a consequence of proteins glycation. It was also found that glycated tau 
can also induce neuronal oxidative stress by generating oxygen free radicals43,49.  
Truncation in PHF-tau which consists in the cleavage of tau at the glutaminic 
acid residue 391 has also been observed. This modification could facilitate aberrant 
tau aggregation44,49. 
Lastly, the deamination is a chemical reaction in which an amide functional 
group is removed, that in tau protein is at aspargine or glutamine residues. This tau 
modification can also have a role in tau aggregation49. 
 
 
1.3.2. The physiological role and the pathological effects of tau      
phosphorylation 
 
Phosphorylation at specific sites and when it is properly coordinated is the 
predominant mechanism that regulates the different roles of tau protein both in 
physiological and pathological conditions (Fig. 8).  
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Figure 8 - Physiological and pathological roles of tau phosphorylation in the cell. Taken from 
Johnson et al. 2004. 
 
Therefore, tau phosphorylation at normal physiological conditions controls a 
variety of processes such as microtubule binding and microtubule assembly47,55, 
neurite outgrowth56, axonal transport57 and cell sorting43. As already mentioned tau 
protein binds to microtubules through the microtubule-binding domains. However 
the phosphorylation within this microtubule-binding domain, at the KXGS motifs, has 
been shown to reduce the binding of tau to microtubules which in physiological 
conditions facilitates the formation of cellular processes47. More specifically is the 
phosphorylation at residues Ser262 and Ser356 that is required for ‘breaking’ the 
binding between tau and microtubules58. Additionally, phosphorylation at Thr231 by 
GSK-3beta also plays a role in diminishing the ability of tau to bind to microtubules55.  
Tau phosphorylation, probably by GSK-3beta, controls the axonal transport given that 
when tau is phosphorylated the affinity to microtubules decreases which makes it 
less effective at competing with kinesin (a protein belonging to a class of motor 
proteins) for binding sites at microtubules and results in a proper anterogradely 
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organelle transport in neurons49,57. It is also thought that tau is involved in the 
regulation of neurite outgrowth and neuronal polarization47. This tau function is also 
controlled by phosphorylation, in the KXGS motifs, since phosphorylation at the 
proximo-distal gradient in neurons56 can be verified. Tau is present in all cell 
compartments, but depending on the cell compartment the levels of tau 
phosphorylation also vary, thus contributing to the cell sorting43. It is also important 
that tau phosphorylation might have a developmental-specific role since it is more 
heavily phosphorylated in fetal than in adult brain52. 
However, under pathological conditions, tau is hyperphosphorylated, meaning 
that it is phosphorylated to a higher degree at normal, physiological sites, and at 
additional “pathological” sites which can affect its physiological role.  Probably this 
hyperphosphorylation is due to an increase in kinase activity and/or a decrease in 
phosphatase activity that causes an imbalance in the 
phosphorylation/dephosphorylation of tau 43. Actually, tau obtained from the brain of 
Alzheimer patients has 40 phosphorylation sites, 28 serines, 10 threonines and 2 
tyrosines, the majority of which can be modified by GSK353. This 
hyperphosphorylation seems to occur in a sequential manner in AD brain. Indeed, the 
phosphorylation of determined sites such as Ser262, Ser202, Thr205 and Thr231 was 
frequently observed in the brain of patients at an early stage of the disease59-61.   
Hyperphosphorylation of tau, in addition to facilitating tau assembly into PHF, 
causes a change in the stabilization of microtubules due to decreased microtubule 
binding which affects the overall organization leading to its dysfunction. Thus the 
localization and organization of other subcellular structures are affected, and 
ultimately increase cell death22. 
 
 
1.3.3. Tau binding proteins 
 
Another important aspect of tau metabolism is its interacting partners, and 
actually many proteins have already been described as interacting with tau both in 
vitro and in vivo (Table 4). These include proteins such as tubulin62, spectrin63, 
calmodulin63, actin64,  kinases involved in tau phosphorylation49 such as GSK-3beta65, 
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PP1 and PP2A49, protein interacting with NIMA 1 (Pin1)24,66, PSEN167-68, alpha-
synuclein69-71, fyn tyrosine kinase72, 14-3-3ξ73,  the heat shock proteins HSP70 and 
HSP9074-75 and ferritin76. 
The most well known tau binding protein is the tubulin as already mentioned 
above. When tau is phosphorylated its affinity to tubulin is reduced which contributes 
to self association and the formation of NFT62. Calmodulin is another tau binding 
protein that only binds tau in the presence of Ca2+ which prevents tau from 
interacting with tubulin leading to an inhibition of microtubule assembly. Tau also 
binds to spectrin, an important protein in the maintenance of plasma membrane 
integrity, but more studies are needed to clarify the physiological relevance of this 
interaction. Interestingly it has also been demonstrated that spectrin binds 
calmodulin, however a possible formation of a complex between these three proteins 
(spectrin-calmodulin-tau) still remains to be elucidated49,63. The interaction between 
tau protein and actin was demonstrated and this interaction of actin occurs through 
the tubulin-binding motif of tau77. This interaction might affect actin polymerization 
and modulation of its dynamics. It is also possible that this interaction helps in the 
organization of the cytoskeletal network through the interaction of microtubules to 
actin78. Another important interaction of tau protein is with Pin1, which is a member 
of the peptidyl-prolyl cis-trans isomerase group of proteins, and can regulate tau 
phosphorylation and facilitates its dephosphorylation by PP2A. In this case there is a 
particularity, since the interaction between these two proteins depends on the 
phosphorylation of tau: Pin1 only binds tau when phosphorylated at Thr23124,49. 
Besides Pin1, the PS1 can also regulate tau phosphorylation. So, PS1 binds directly to 
tau and also to the GSK-3beta, and both bind PS1 in the same domain68. It was 
observed that in PS1 mutants there is an increase in the association with the GSK-
3beta that leads to increased phosphorylation of tau65. The alpha-synuclein is another 
known tau binding protein that stimulates tau phosphorylation through protein 
kinase A (PKA) and more specifically the interaction is between the C-terminal of 
alpha-synuclein and the microtubule-binding domain of tau. Since this interaction 
modulates tau phosphorylation, indirectly affecting the stability of microtubules71. 
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Table 4 – Tau binding proteins and remarks of these interactions. 
Protein Remarks Reference 
Tubulin - Promotes microtubule assembly Tseng et al., 1999 
Calmodulin 
- Block tau and tubulin interaction 
- Inhibition of microtubule assembly 
Carlier et al., 1984 
Avila et al., 2004 
Spectrin 
- Physiological relevance of this interaction 
is unknown 
Carlier et al., 1984 
Actin 
- Interaction affects actin polymerization 
and modulates its dynamics 
- Organization of cytoskeleton network 
Yu et al., 2006 
Correas et al., 1990 
Pin-1 
- Regulates tau phosphorylation 
- Facilitates dephosphorylation of tau by 
PP2A 
- Pin-1 binds to p-tau at Thr231 
Gendron et al., A 
Agarwal-mawal et al., 2003 
Avila et al., 2004 
PS1 
- Regulates tau phosphorylation 
- Binds to GSK-3β 
Ramirez et al., 2001 
Shepherd et al., 2004 
Takashina et al., 1993 
α-synuclein 
- Stimulates PKA tau phosphorylation 
- Indirectly affects  microtubules stability 
 
Shepherd et al., 2004 
Jellinger et al., 2011 
Jensen et al., 1999 
Fyn tyrosine 
kinase 
- Induces tyrosine phosphorylation of tau 
- Allows signals transduced through fyn to 
alter microtubule cytoskeleton 
 
Lee et al., 1998 
Klein et al., 2002 
14-3-3ξ 
- Stimulates tau phosphorylation through 
cAMP-dependent protein kinase 
 
Hashiguchi et al., 2000 
HSP70 and 
HSP90 
- Promotes tau solubility 
- Promotes tau binding to microtubules 
- Prevents tau aggregation 
 
Dou et al., 2003 
Jinwal et al., 2009 
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The fyn tyrosine kinase, a src-family non-receptor tyrosine kinase, interacts 
with a PXXP motif in the proline rich region of tau through its SH3 domains. The 
interaction results in the tyrosine phosphorylation of tau which results in the 
alterations on microtubules by signals transduced through fyn64,79. 14-3-3ξ is another 
protein involved in the abnormal phosphorylation in AD since it is an effector of tau 
protein phosphorylation. More specifically, this protein binds to microtubule-binding 
domain of tau (phosphorylated and nonphosphorylated) and stimulates tau 
phosphorylation through cAMP-dependent protein kinase73. Increasing levels of heat 
shock proteins (HSP70 and HSP90), which interact with tau, promote tau solubility 
and binding to microtubules preventing aggregation74. 
Currently, all the tau interacting proteins and all the role of these interactions 
have not been described. 
 
 
1.4. Relationship between Abeta peptide and tau phosphorylation 
 
An important issue in the pathogenesis of AD that is not clear is the association 
between the two histopathological hallmarks of the disease: amyloid plaques and 
neurofibrillary tangles. Currently, the most accepted hypothesis is the Amyloid 
hypothesis in which the accumulation of the Abeta peptide is a central event in the 
pathogenesis of AD (Fig. 9)80-82. According to this hypothesis the pathological 
processing of APP leads to an increased Abeta concentration in brain that is the main 
component of the amyloid plaques. The plaques lead to neuronal death and 
secondarily to tau pathology80.  
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Figure 9 – Pathological cascades of AD. Primarily APP is cleaved by beta-secretase followed by gamma-
secretase to produce Abeta1-42 and other shorter fragments. Subsequently Abeta1-42 aggregates resulting in 
oligomers and amyloid fibrils that eventually are deposited as amyloid plaques. The toxicity of oligomers and 
amyloid plaques can lead to the cascade of tau hyperphosphorylation. Tau normally binds to microtubules 
promoting stability. Following phosphorylation, tau dissociates from microtubules and instead aggregates into 
NFT which in turn can eventually cause increased cytoskeleton flexibility and neuronal death. Taken from Anoop 
et al., 2010. 
 
 
Indeed, an earlier study from Takashima et al. described that 20µM of Abeta1-43 
and Abeta25-35 are toxic for rat primary hippocampal cultures and induces an increase 
on tau phosphorylation mediated by the activation of the GSK-3beta and tau tubulin 
kinase65. In 2002, Zheng et al. reported that aggregated Abeta25-35 induces tau 
phosphorylation at Thr181, Ser202 and Thr205 residues in a time and concentration 
dependent manner in rat septal cultured neurons and activated the MAPK and GSK-
3beta82. Furthermore, Sul et al. showed that Abeta25-35 increased tau phosphorylation 
at disease-relevant sites, such as Ser202, and then induced aggregation of tau 
proteins into NFTs, mediated by GSK-3beta. In this study, PC12 cells were exposed to 
10µM of Abeta25-35 for 24 hours83. In marked contrast to these findings, Davis et al. 
found that 100µM of aggregated Abeta25-35 in 8-day-old rat primary cortical neuronal 
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cultures induced no obvious changes in the phosphorylation state of tau at Ser202 
and Thr205 residue even if there is an evident toxic effect 84.  
A more recent study, revealed that 10µM of Abeta1-42 can also potentiate 
hyperphosphorylation of tau at Ser202 in differentiated PC12 cells in a time-
dependent manner being that maximal increase could be achieved within 24 hours85. 
Another report from Bulbarelli et al. also showed that in hippocampal neurons the tau 
phosphorylation at Ser262 residue progressively increased during Abeta1-42 (2,5µM) 
treatment and death significantly increased in a time-dependent manner reaching 
60% in 24hours86. 
Moreover, it was shown that 5µM of Abeta1-40 activates c-Abl tyrosine kinase 
for 30 minutes and 3 hours of exposure in rat hippocampal neurons, with a higher 
fold increase at the 30 minutes time point. Then c-Abl  participates in Abeta-induced 
tau phosphorylation through cdk5 activation, by its Tyr15 phosphorylation 87. 
Besides the effects of Abeta in mediating the activation of kinases involved in tau 
phosphorylation, it has also been described by Vintém et al. that Abeta (Abeta1-40, 
Abeta1-42 and Abeta25-35) specifically inhibits different PP1 isoforms at low 
micromolar (20 and 50µM) concentrations both in vitro and ex vivo88.  
Thus, it is thought that Abeta binds to certain cell receptors and interacts with 
the signaling pathways that regulate the phosphorylation of tau protein, and multiple 
kinases and phosphatases are likely to be involved (Fig. 10) 89. Furthermore, 
degradation of hyperphosphorylated tau by proteasome is inhibited by the actions of 
Abeta 87. 
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Figure 10 – Involvement of multiple interacting candidate tau kinases and phosphatases in Abeta-induced 
neurodegeneration. Extracellular Abeta activates candidate protein kinases through several different 
mechanisms, including those represented in this summary. Numerous interactions between protein 
serine/threonine (pink) and tyrosine (Abl and Fyn, pale blue) kinases as well as phosphatases (PP1 and PP2A, 
yellow) have been reported. Dashed and solid lines indicate indirect and direct interactions, respectively, and red 
lines indicate inhibitory relationships between enzymes. CaMKII: calcium-calmodulin kinase II; MARK: 
microtubule affinity-regulating kinase; MEK: mitogen-activated protein kinase; SAPK: stress-activated protein 
kinase. Taken from Hanger et al. (2009)53.  
 
 
Thus although several phosphorylation relevant events have been studied, the 
cross talk between signaling cascades and all the phosphatase and kinases involved 
have not been fully elucidated. Clarification of these aspects would undoubtedly be an 
important step towards developing novel effective therapeutic strategies. 
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2. Aims of the dissertation 
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Alzheimer´s disease is a neurodegenerative disorder characterized by two 
major histopathological hallmarks: extracellular AP and intracellular NFTs. The latter 
is primarily composed of hyperphosphorylated tau protein. According to the amyloid 
cascade hypothesis, the formation of AP precedes tau pathology, which in turn is 
induced by Abeta oligomers. 
However some questions remain regarding the pathological 
hyperphosphorylation of tau protein. Another important feature of tau metabolism is 
its interacting proteins; more importantly the proteins that interact specifically with 
phosphorylated tau (p-tau). The different tau interacting proteins provide relevant 
information with respect to pathological and protective pathways that are active at 
different stages of the disease process. These pathways are attractive targets for 
therapeutical intervention. 
 
 
Thus the specific aims of this dissertation are to: 
 Determine the role of Abeta on tau phosphorylation; 
 
 Establish the protein phosphatases involved in tau 
dephosphorylation. 
 
 Identify the proteins that interact with the tau protein and with 
phosphorylated tau (p-tau) and evaluate the effects of Abeta on 
these interactions; 
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3. Materials and Methods 
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3.1. Antibodies 
 
  The following primary antibodies were used: rabbit polyclonal p-tau Ser262 
antibody (Santa Cruz Biotechnology, Inc) directed against the phosphorylated tau at 
Ser262; mouse monoclonal anti-phosphorylated tau antibody, clone AT8 (Pierce) 
which specifically recognizes phosphorylated tau at Ser202 and Thr205; mouse 
monoclonal anti-tau antibody, clone Tau-5 (Millipore) to detect all phosphorylated 
and non-phosphorylated isoforms of tau; and mouse monoclonal anti-β-Tubulin 
antibody (Invitrogen) directed against β-Tubulin (table 5). 
Horseradish peroxidase-conjugated anti-mouse (1:5000) and anti-rabbit 
(1:5000) IgGs were used as secondary antibodies (Amersham Pharmacia) for 
immunoblotting (table 5). 
 
 
Table 5- Summary of the antibodies used to detect target proteins and specific dilutions used for the 
different assays. The specific dilutions used for the different assays are also indicated. IB: Immunoblotting; IP: 
immunoprecipitation. 
 
 
 
 
 
Antibody Target Protein/Epitope Dilution 
Expected bands 
site (KDa) 
p-tau Ser262 p-tau at Ser 262 
 
IB dilution:   1:1000 
IP dilution:  1:150 
46-68 
AT8 
p-tau at Ser202 and 
Thr205 
 
IB dilution:   1:1000 46-68 
Tau-5 total tau 
 
IB dilution:   1:500 
IP dilution:  1:100 
46-68 
Anti - β-Tubulin β-Tubulin IB dilution: 1:1000 50 
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3.2. Cell culture 
 
3.2.1. Primary Neuronal Cultures 
 
Rat cortical and hippocampal cultures were established from Wistar Hannover 
18 days rat embryos whose mother was euthanized by rapid cervical dislocation. 
After cortex and hippocampus dissection, tissues were dissociated with trypsin (0.23 
or 2.25 mg/ml for cortical or hippocampal cultures, respectively) and 
deoxyribonuclease I (0.15 or 1.5 mg/ml for cortical or hippocampal cultures, 
respectively) in Hank’s balanced salt solution (HBSS) for 5 minutes at 37oC. Cells 
were washed with HBSS supplemented with 10% FBS to stop trypsinization, 
centrifuged at 1000 rpm for 2 minutes, and further washed and centrifuged with 
HBSS for serum withdraw. Cells pellet was ressuspended in complete Neurobasal 
medium (Gibco), a serum-free medium combination, which is supplemented with 2% 
NB27 (Gibco). The medium was also supplemented with glutamine (0.5 mM), 
gentamicin (60µg/ml) and with or without glutamate (25µM) for hippocampal or 
cortical cultures, respectively. Viability and cellular concentration were assessed by 
using the Trypan Blue excluding dye (Sigma). For immunoblotting analysis cortical 
and hippocampal primary neuronal cultures were plated on poly-D-lysine-coated six-
well plates at a density of 0.8x106 cells per well. For immunoprecipitation analysis, 
cortical primary neuronal cultures were plated on poly-D-lysine-coated 100 mm 
plates at a density of 6.0x106 cells per plate. Cells were maintained in 12 ml of 
Neurobasal medium in 100 mm plates and 2 ml of Neurobasal medium in six-well 
plates in an atmosphere of 5% CO2 at 37oC for 10 days before being used for 
experimental procedures. Five days after plating, ¼ of medium was replaced with 
glutamate-free complete Neurobasal medium for both cortical and hippocampal 
cultures.  
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3.3. Cortical and hippocampal neurons treatment with Abeta 
 
To evaluate the effects of Abeta on tau phosphorylation at residues Ser202, 
Thr205 and Ser262, 10 days cortical and hippocampal neurons were incubated with 
different concentrations of Abeta peptides for different periods of time.  
Synthetic Abeta1-42 , Abeta42-1 and Abeta25-35 peptides (American Peptide) were 
dissolved in water to prepare 1mM stock solutions. Exposure of cells to Abeta was 
preceded by an aggregation step, which was achieved by incubating the different 
peptides for 48 hours at 37oC with PBS at concentration of 100µM. 10 days cortical 
and hippocampal neurons were used and washed twice with PBS before Abeta 
treatments. Cells were then incubated for 30 minutes, 3 hours and 24 hours in 
Neurobasal medium free of B27 with different Abeta concentrations: 0,5µM Abeta1-42, 
2µM Abeta1-42, 10µM Abeta1-42 and 20µM Abeta1-42 for immunoblotting analysis.  
After the specific treatments, media and cells were collected. The media were 
centrifuged at 300 g for 5 minutes, the supernatant transferred to a new microtube 
and then made up to 1% SDS and boiled for 10 minutes.  The cells were collected with 
RIPA buffer and sonicated twice during 5 seconds. RIPA buffer was used because 
enables an efficient cell lysis and protein solubilization while avoiding protein 
degradation and interference with the protein´s immunoreactivity and biological 
activity. 
 
 
3.4. Cortical and hippocampal neurons treatment with protein phosphatase 
inhibitors 
 
In order to establish the protein phosphatases (PPs) involved on tau 
dephosphorylation at residues Ser202, Thr205 and Ser202, rat primary neuronal 
cultures were incubated with a PPs inhibitor: okadaic acid..  
Stock solution of okadaic acid (0.5µM, Calbiochem) was prepared and used for 
the following incubations. Rat primary cortical neuronal cultures were plated as 
described above (section 3.2.1.) and washed twice with PBS before okadaic acid 
treatments. 10 days cortical and hippocampal neurons were incubated with okadaic 
Abeta dependent tau phosphorylation 
47 
 
acid in Neurobasal medium free of B27 for 30 minutes and 3 hours at different 
concentrations in order to inhibit specifically different PPs (table 6).  
After the appropriate treatments, media and cells were collected as described 
in section 3.3.  
 
 
Table 6 – Range of IC50 values of protein phosphatase inhibition. All Values expressed as 
nanomolar (nM). PP, protein phosphatase; IC50, 50% inhibition concentration. Adapted from Swingle 
et al., 2007 90. 
Inhibition of Ser/Thr Protein Phosphatase activity (IC50) 
Drug PP1 PP2A PP2B PP4 PP5 PP7 
 
Okadaic acid 
(OA) 
15-50 0.1 – 0.3 4000 0,1 3.5 >1000 
 
 
3.5. BCA protein quantification assay 
 
Protein content determination of the cellular lysates was carried out using the 
BCA Protein Assay (Pierce). This assay is a detergent-compatible formulation based 
on bicinchoninic acid (BCA) for colorimetric detection and quantification of total 
protein. The method combines the reduction of Cu2+ to Cu+ by protein in an alkaline 
medium (the biuret reaction) with high sensitivity and selective colorimetric 
detection of the cuprous cation (Cu+) using a unique reagent containing bicinchoninic 
acid. The purple-coloured reaction product of this assay is formed by chelation of two 
molecules of BCA with one cuprous ion. This water soluble complex exhibits a strong 
absorbance at 562 nm that is linear with increasing protein concentration over a 
working range of 20µg/ml to 2000µg/ml. The standards were prepared as described 
in table 7, and final volume of each was equal to 50µL. 
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Table 7 - Standard preparation; BSA, bovine serum albumin; WR, working reagent. 
Standards BSA (µL) 
Extraction 
buffer (µL) 
Protein Mass (µg) 
P0 0 50 0 
P1 1 49 2 
P2 2 48 4 
P3 5 45 10 
P4 10 40 20 
P5 20 30 40 
P6 40 10 80 
 
Briefly, the quantitative analyses were carried out using 10 µL of the collected 
cell lysates (IB) and 5 µL of the collected cell lysates (IP) (final volumes of 50 µL were 
adjusted with extraction buffer). After preparation of both samples and standards 
they were incubated at 37oC for 30 minutes with 1 ml of working reagent, which is 
prepared with 50 parts of reagent A to 1 part of the reagent B. After incubation the 
tubes were cooled to RT and the absorbances were then measured at 562 nm. A 
standard curve was prepared by plotting the O.D. value for each BSA standard against 
its concentration. Using this standard curve the protein concentration of each sample 
was determined. Duplicates of samples and standards were always prepared. 
 
3.6. SDS - Polyacrylamide gel electrophoresis 
 
SDS–Polyacrylamide gel electrophoresis (SDS-PAGE) is an analytical technique 
of electrophoresis of proteins on polyacrylamide gels under conditions that ensure 
dissociation and characterization of proteins and peptides in mixtures. In SDS-PAGE 
proteins are separated according their molecular weight and negative net charge due 
to SDS-amino acid binding since SDS is an anionic detergent that denatures proteins 
by wrapping around the polypeptide backbone, conferring a negative charge to the 
polypeptide in proportion to its length. 
Samples were subjected to 5-20% gradient SDS-PAGE in a Hoefer 
electrophoresis system. The gradient gel were prepared and allowed to polymerize 
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for 45 minutes at room temperature. Subsequently, the stacking gel solution was 
prepared and loaded on the top of gradient gel. A comb was inserted and the gel was 
left to polymerize for 30 minutes at room temperature. Prior to loading, the samples 
were prepared by the addition of ¼ volume of 4x Loading buffer (LB), boiled for 10 
minutes and spinned down. The samples were carefully loaded into the wells, and 
gels were run at 90 mA for approximately 3 hours. Molecular weight markers 
(Kaleidoscope Prestained Standards and Dual Colour Prestained Standards – Broad 
range, Bio Rad) were also loaded and resolved side-by-side with the samples. 
 
 
3.7. Immunoblotting  
 
After electrophoresis, proteins can be transferred from a gel to a solid support, 
while keeping their positions and then can be visualized with specific antibodies. In 
this work, proteins were electrophoretic transferred to nitrocellulose membranes 
(Whatman®) for 18 hours at 200 mA. After transfer the proteins were detected using 
specific antibodies against the proteins of interest. Once the immunoblotting protocol 
is antibody specific, the protocols used were summarized in the table 8. 
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Table 8 – General immunoblotting protocol used for each antibody. ON, overnight; RT, room-
temperature; min, minutes; h, hours. 
Antibody Hydration 
Blocking 
Agent 
Primary 
Antibody 
Washings 
Secondary 
Antibody 
Washings 
Detection 
method 
p-tau 
Ser262 
-1x TBS  
-5 min 
-5% BSA in 
1x TBS-T  
-4 h RT 
- 5% BSA in 
1x TBS-T 
- 4 h RT + 
ON at 4oC 
-1x TBST     
- 3 times  
- 10 min  
-5% BSA in 
1x TBST 
- 2 h RT 
-1x TBST     
- 3 times  
- 10 mi 
ECL Plus 
AT8 
- 1x TBS  
 - 5 min 
-5% low fat 
dry milk in 
1x TBS-T  
- 4 h RT 
- 5% low 
fat dry milk 
in 1x TBS-T  
- 4 h RT + 
ON at 4oC 
-1x TBST     
- 3 times  
- 10 min 
-3% low fat 
dry milk in 
1x TBS-T 
- 2 h RT 
-1x TBST     
- 3 times  
- 10 min 
ECL Plus 
Tau-5 
- 1x TBS 
-5 min 
- 5% BSA in 
1x TBS-T 
- 4 h RT 
- 5% BSA in 
1x TBS-T 
- 4 h RT + 
ON at 4oC 
-1x TBST     
- 3 times  
- 10 min 
-5% BSA  in 
1x TBS-T 
- 2 h RT 
-1x TBST     
- 3 times  
- 10 min 
ECL 
β-Tubulin 
- 1x TBS 
-5 min 
-5% low fat 
dry milk in 
1x TBS-T  
- 4 h RT 
- 5% low 
fat dry milk 
in 1x TBS-T  
- 2 h RT 
-1x TBST     
- 3 times  
- 10 min 
-3% low fat 
dry milk in 
1x TBS-T 
- 2 h RT 
-1x TBST     
- 3 times  
- 10 min 
ECL 
 
 
Immunoblotting of the transferred proteins was performed by initially soaking 
the membranes in 1x TBS for 5 minutes and then blocking non-specific binding sites 
of the primary antibody by incubating the membrane with 5% non-fat dry milk/5% 
BSA in 1x TBST for 4 hours. The membrane was further incubated with the primary 
antibody, washed with 1x TBST, incubated with secondary antibody, washed again in 
1x TBST and then incubated for 1 minute at RT with ECL detection kit or for 5 
minutes with the ECL plus detection kit (GE Healthcare) in a dark room, as described 
in table 8 for each specific primary antibody. 
ECLTM Western blotting from GE Healthcare is a chemiluminescent (light 
emitting non-radioactive) method for detection of immobilized specific antigens, 
conjugated directly or indirectly with horseradish peroxidase-labelled antibodies. 
The ECL reaction is based on the oxidation of the cyclic diacylhydrazide luminal and 
ECL plus utilizes a technology based on the enzymatic generation of an acridinium 
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ester, which produces a more sensitive light emission of longer durations than ECL. 
After exposure to X-Ray film (Kodak) films were developed and fixed with 
appropriate solutions (Kodak). 
3.8. Co- immunoprecipitation and mass spectrometry analysis 
 
To evaluate the effects of Abeta on tau binding proteins, more specifically on p-
tau binding proteins rat primary cortical neuronal cultures were incubated with the 
Abeta peptide and okadaic acid for 3 hours.  
In our experimental procedure the immunoprecipitation was carried out using 
Dynabeads® Protein G (Invitrogen) because magnetic handling is fast and easier, 
efficient, extremely gentle on our target proteins and eliminate background since 
there are less non-specific binding. The principle was the same for other 
immunoprecipitation procedures: primary antibody is added to the Dynabeads® 
Protein G and during a short incubation the antibody will bind to the Dynabeads via 
their Fc region. The tube is then placed on a Dynal magnet, where the beads will 
migrate to the side of the tube facing the magnet and allow for easy removal of the 
supernatant. The bead-antibody complex may now be used for immunoprecipitation. 
Bound material is easily collected utilizing the unique magnetic properties of the 
Dynabeads® (Fig. 11). Magnetic separation facilitates washing, buffer changes and 
elution. 
Stock solution of aggregated Abeta1-42 and okadaic acid were prepared as 
described in section 3.3 and 3.4.  Cells were plated as described above (section 3.2.1), 
washed twice with PBS and incubated for 3 hours with 10µM Abeta1-42 and 0.25µM 
okadaic acid in Neurobasal medium free of B27. After the appropriate treatments, the 
media were removed and cells were gently scrapped off the culture plate with MOPS 
lysis buffer and the lysates collected. The lysates were sonicated three times during 
10 seconds. The MOPS buffer was used because according the recommendations from 
Kinexus the lysis must be performed with a pH buffering agent that do not contain 
reactive amine groups, and for example, the TRIS cannot be used.  
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Figure 11 –A. Principle of immunoprecipitation of antigen using Dynabeads Protein G; B. Example of a 
Dynal magnet. Taken from the manufacturer datasheet (Invitrogen). 
 
Thus after BCA protein quantification of samples (as described above) mass 
normalizes lysates were precleared with 15 µL Dynabeads protein G for 1 hour at 4OC 
with agitation. Then the supernatant was transferred to a new microtube and 60 µL of 
Dynabeads protein G plus the primary antibody (Tau-5 and p-Tau Ser262 at 
respective dilutions) was added and incubated overnight with shaking at 4OC. The 
supernatant was then removed and the beads washed four times with 400 µL of 
washing solution (3% BSA/PBS) for 15 minutes with agitation at 4OC. After the last 
wash the supernatant was fully discarded and the beads were resuspended in 45 µL 
of 1xLB (Loading buffer) and boiled for 10 minutes. The immnunoprecipitates were 
frozen at -80OC and shipped to Kinexus to Mass Spectrometry Services PIMS (Protein 
ID by mass spectrometry, Fig.11). Our immunoprecipitates were subjected to SDS-
PAGE and the gel stained with Coomassie blue. Then the bands of interest were 
excised from the SDS-PAGE gel, subjected to trypsin digestion and analyzed by high-
resolution mass spectrometry, performed on an LC-MS/MS (Thermo Electron LTQ – 
Orbitrap), to determine their accurate masses. Finally, a search of the appropriate 
protein sequence databases using a Mascot search was performed to determine a 
matching mass pattern that can lead to a definitive identification of the protein. 
 
A. B. 
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Figure 12 – Methodology of protein identification by mass spectrometry using agarose beads 
without antibody as a negative control (Taken from the manufacturer datasheet). In our 
experimental procedure we performed the immunoprecipitations, using tau specific antibodies and 
Dynabeads protein G instead of agarose beads (Aveiro Laboratory). As negative control we use 
Dynabeads without antibody (Aveiro laboratory). The immunoprecipitates were sent to Kinexus and 
were further analyzed by SDS-PAGE followed by LC-MS/MS (Kinexus). 
 
 
 
3.9. Quantification and statistical analysis 
 
Quantitative analyses of immunoblots were performed using the Quantity One 
densitometry software (Bio-Rad). This system quantifies band intensity and 
correlates it to protein levels.  
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4. Results 
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4.1. Abeta effects on tau phosphorylation at Ser202, Thr205 and Ser262 
residues 
 
4.1.1. Rat primary cortical neuronal cultures 
 
Recent studies have provided new evidence showing that Abeta peptide and 
tau reciprocally interact in mediating neurodegenerative processes. However, the 
functional relevance between Abeta and hyperphosphorylated tau in the pathway 
leading to neurofibrillary pathology is unclear. To determine whether Abeta could 
promote tau phosphorylation, we exposed rat primary cortical neurons to aggregated 
Abeta1-42 at increasing concentrations (0.5, 2, 10 and 20µM) for 30 minutes, 3 and 24 
hours. Following this period the cell lysates were collected and further analyzed by 
SDS-PAGE and immunoblotting using Tau5, AT8 (phospho-tau Ser202 and Thr205), 
p-tau Ser262 and β-Tubulin antibodies. The results are presented in Fig. 13 and Fig. 
14, the antibodies used in each of the figures is indicated in figure legend.  
As indicated in Fig. 13A, when cortical neurons were incubated with increasing 
concentrations of aggregated Abeta1-42 for 30 minutes and 3 hours, the levels of total 
tau protein detected with Tau5 antibody did not fluctuate markedly although there 
was a tendency to decrease. In contrast for the 24 hour period a decrease in total tau 
protein levels was detected, particularly with the two higher Abeta concentrations.  
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Figure 13 - Abeta effects on tau phosphorylation at both Ser202 and Thr205 residues. Rat primary cortical 
neuronal cultures were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes, 3 hours and 24 hours 
with aggregated Abeta1-42 (0.5, 2, 10 and 20µM). Cell lysates were collected and analyzed by immunoblotting with 
Tau5 antibody which recognizes total tau (A), AT8 antibody which recognizes tau phosphorylated at Ser202 and 
Thr205 residues (B) and β-Tubulin antibody (C). D – Ratio between phospho-tau and total tau. Data was obtained 
from triplicate experiments (n=3).  
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The state of tau phosphorylation (Fig. 13B) at both Ser202 and Thr205 
residues (recognized by AT8 antibody), upon treatment for 30 minutes and 3 hours 
with aggregated Abeta1-42 remains almost the same as the controls.  However, at the 3 
hour time point of incubation, with 0.5µM of aggregated Abeta1-42, we observed a 
slight increase of tau phosphorylation of approximately 10% and this increase is also 
evident at the 24 hour time point. Additionally, after 24 hours of Abeta treatment, 
there is a robust decrease of tau phosphorylation with 10µM and 20µM of aggregated 
Abeta1-42, approximately 70% and 85%, respectively (Fig. 13B).  β-Tubulin was used 
as loading control (Fig. 13C). In order to have a clear idea of the phosphorylation 
pattern on these 2 residues, following Abeta1-42 treatment we calculated the ratio of 
phosphorylated tau protein (p-tau) versus total tau protein (total tau), Fig. 13D. The 
analysis of this ratio revealed that tau phosphorylation upon Abeta1-42 treatment, 
Ser202 and Thr205 exhibits a tendency to decrease after 30 minutes and 3 hours. In 
contrast after 24 hours of treatment with Abeta1-42 the tendency to decrease is 
evident at the higher Abeta1-42 concentrations (10µM and 20µM).  
 
Regarding the levels of tau phosphorylation at Ser262, residue recognized by 
p-tau Ser262 antibody (Fig. 14B), quantifications revealed that it remains almost 
unvaried upon Abeta1-42 treatment for 30 minutes. However, with 3 hours after Abeta 
treatment we observed a different pattern. At 0.5µM and 2µM Abeta1-42 
concentrations, tau phosphorylation at Ser262 increased by approximately 10-20%, 
but at 20µM Abeta1-42 concentration the response was reversed and tau 
phosphorylation decrease to 70% of control levels. At 24 hours of treatment the 
pattern of tau phosphorylation is similar to that observed at 3 hours, although this 
biphasic response is more marked.  
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Figure 14 - Abeta effects on tau phosphorylation at Ser262 residue. Rat primary cortical neuronal cultures 
were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes, 3 hours and 24 hours with aggregated 
Abeta1-42 (0.5, 2, 10 and 20µM). Cell lysates were collected and analyzed by immunoblotting with Tau5 antibody 
which recognizes total tau (A) p-tau Ser262 antibody which recognizes tau phosphorylated at Ser262 residue  (B) 
and β-Tubulin antibody (C). D – Ratio between phospho-tau at residue Ser262 and total tau. Data was obtained 
from triplicate experiments (n=3). 
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Consequently the ratio of phospho-tau (Ser262) versus total tau was 
calculated, Fig. 14D. This ratio shows that upon 30 minutes and 3 hours of Abeta 
treatment phosphorylation at the residue drops only for the higher Abeta1-42 
concentration.  However, when we treat the cortical neurons for 24 hours the 
increase of tau phosphorylation on Ser262 residue increases as a percentage of total 
tau (Fig. 14D). At this time point β-Tubulin (Fig. 14C) remains constant.  
 
 
4.1.2. Rat primary hippocampal neuronal cultures  
 
To evaluate the effects of Abeta peptide on tau phosphorylation in rat primary 
hippocampal neuronal cultures, we treated these cells as for cortical neuronal 
cultures described in section 4.1.1. The results regarding the effect of Abeta1-42 
treatment on tau phosphorylation on Ser202 and Thr205 residues are presented in 
Fig. 15. In Fig. 15A we can observe that upon 30 minutes of exposure to 0.5, 2 and 
10µM of aggregated Abeta1-42 the levels of total tau protein detected with Tau5 
antibody decrease in a dose-dependent manner,  although there is an increase similar 
to control with 20µM of Abeta1-42. This pattern is the same after 24 hours of exposure, 
although the decrease is maintained for all Abeta1-42 concentrations.  At 3 hours of 
exposure the increasing Abeta concentrations do not affect the total tau protein 
levels.  
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Figure 15 - Abeta effects on tau phosphorylation at both Ser202 and Thr205 residues. Rat primary 
hippocampal neuronal cultures were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes, 3 hours 
and 24 hours with aggregated Abeta1-42 (0.5, 2, 10 and 20µM). Cell lysates were collected and analyzed by 
immunoblotting with Tau5 antibody which recognizes total tau (A), AT8 antibody which recognizes tau 
phosphorylated at residues Ser202 and Thr205 (B) and β-Tubulin (C). D – Ratio between phospho-tau at residues 
Ser202 and Thr205 and total tau. Data was obtained from duplicate experiments (n=2). 
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For hippocampal neurons treated with Abeta1-42, the immunoblots were 
probed with the AT8 antibody (Fig. 15B) and we can observe that levels of tau 
phosphorylated at Ser202 and Thr205 residues decreased in a concentration 
dependent manner at all the three time points, being more evident for the 24 hour 
treatment. The actual pattern of percentage tau phosphorylation at both these 
residues is revealed by the p-tau/total tau ratio (Fig. 15D). Therefore, upon 30 
minutes of treatment we can observe a tendency of increased tau phosphorylation 
with 0.5, 2 and 10µM of Abeta1-42. With 3 and 24 hours of treatment there is a 
decrease on tau phosphorylation, as a percentage of total tau, in a dose- dependent 
manner, that is more evident at the 3 hour time point.  
 
The absolute phosphorylation levels of tau protein at residue Ser262 are 
shown in Fig. 16B. These decrease upon treatment with Abeta1-42, in a dose-
dependent manner, for the three periods of time, being more evident at 3 hours of 
exposure. However, when is taken into account the phosphorylation levels in 
proportion to the total tau protein expression (Fig. 16D) the pattern is similar to that 
observed with p-tau alone (Fig. 16B), being that at both conditions, 30 minutes and 3 
hours of treatment, it remains almost the same with exception of the incubation with 
10µM of Abeta1-42 for 30 minutes, where we can observe a slight increase on 
phosphorylated tau levels. When hippocampal neurons are exposed to increasing 
concentrations of Abeta1-42 for 24 hours it causes an increase on tau phosphorylation 
that is dose-dependent until the 10µM and not so evident with 20µM. 
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Figure 16 - Abeta effects on tau phosphorylation at Ser262 residues. Rat primary hippocampal neuronal 
cultures were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes, 3 hours and 24 hours with 
aggregated Abeta1-42 (0.5, 2, 10 and 20µM). Cell lysates were collected and analyzed by immunoblotting with Tau5 
antibody which recognizes total tau (A), p-tau Ser262 antibody which recognizes tau phosphorylated at Ser262  
(B) and β-Tubulin antibody (C). D – Ratio between phospho-tau at residue Ser262 and total tau. Data was obtained 
from duplicate experiments (n=2). 
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4.2. Protein phosphatases involved in tau dephosphorylation at Ser202, Thr205 
and Ser262 residues 
 
4.2.1. Rat primary cortical neuronal cultures 
 
To elucidate the probable protein phosphatases (PPs) involved on tau 
dephosphorylation at Ser 202, Thr205 and Ser262 residues, we examined the effect of 
a PP inhibitor, okadaic acid (OA). Cortical neurons were exposed to different 
concentrations of OA for two periods of time (30 minutes and 3 hours). As described 
above, cell lysates were collected and separated by SDS-PAGE, and further analyzed 
by immunoblotting with Tau5, AT8, p-tau Ser262 and β-Tubulin antibodies.  
 
4.2.1.1. Okadaic acid  
 
Upon 30 minutes and 3 hours exposure of cortical neurons to increasing 
concentrations of OA (0.1, 0.25, 50, 500 and 5 µM) the levels of total tau protein do 
not significantly differ from the control (Fig. 17A). There is, however, for the two 
higher concentrations of OA (500 and 5 µM) for both 30 minutes and 3 hours of 
exposure, a shift that is indicative of a significant difference in electrophoretic 
mobility, consistent with increased levels of tau phosphorylation, as already 
described54. Relative to phosphorylated tau at Ser202 and Thr205 residues (Fig. 17B) 
we can observe that lower concentrations of OA (0.1 and 0.25µM), when PP2A is 
inhibited,  are not sufficient to induce alterations in the level of phosphorylation for 
both time points.  
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Figure 17 - Okadaic acid effects on tau phosphorylation at both Ser202 and Thr205 residues. Rat primary 
cortical neuronal cultures were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes and 3 hours 
with okadaic acid (0.1, 0.25, 50, 500 and 5000 nM). Cell lysates were collected and analyzed by immunoblotting 
with Tau5 antibody which recognizes total tau (A), AT8 antibody which recognizes tau phosphorylated at Ser202 
and Thr205 residues (B) and β-Tubulin antibody (C). D – Ratio between phospho-tau at Ser202 and Thr205 and 
total tau. Data was obtained from duplicate experiments (n=2). 
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Exposure to 50 nM, 500 nM and 5 µM of OA already induces a marked increase 
on tau phosphorylation both at 30 minutes and 3 hours, suggesting an involvement of 
PP1 on tau dephosphorylation at both these residues (Ser202 and Thr205). Since the 
total tau protein expression does not significantly alter, as mentioned above, the 
pattern of tau phosphorylation observed in the phospho-tau/total tau ratio (Fig. 17D) 
is similar to the pattern already discussed (Fig. 17B). 
The pattern of protein phosphatase inhibition with respect to tau 
phosphorylation of Ser262 is different to the situation described above. At 0.1 nM OA 
concentration there appears to be an inhibition characteristic for PP2A inhibition 
(table 6, section 3.4.). This is true for 30 minutes and 3 hours (Fig. 18B) and also 
when data is expressed as a percentage of the total tau (Fig. 18D). The involvement of 
PP1 is also evident given that increased tau phosphorylation is detected when OA is 
added at 50 nM (30 minutes, Fig. 18B and Fig. 18D). Prolonged exposure to OA, for 3 
hours, confirmed the involvement of PP2, and excluded the possibility of PP2B, given 
that no further increase were obtained at OA concentrations of 5µM. Thus, with 
respect to residue Ser262, PP1 is clearly involved, PP2A also appears to be relevant 
but PP2B does not appear to be involved.  
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Figure 18 - Okadaic acid (OA) effects on tau phosphorylation at Ser262 residue. Rat primary cortical 
neuronal cultures were incubated at 37oC in Neurobasal medium free of B27 for 30 minutes and 3 hours with 
okadaic acid (0.1, 0.25, 50, 500 and 5000 nM). Cell lysates were collected and analyzed by immunoblotting with 
Tau5 antibody which recognizes total tau (A), p-tau Ser262 antibody which recognizes tau phosphorylated at 
Ser262 (B) and β-Tubulin antibody (C). D – Ratio between phospho-tau at residue Ser262 recognized and total 
tau. The respective quantitative data is also presented. Data was obtained from duplicate experiments (n=2). 
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4.3. Abeta effects on tau and p-tau binding proteins 
 
4.3.1. Rat primary cortical neuronal cultures 
 
In order to accomplish this aim of identifying the tau binding proteins and 
more specifically the phosphorylation dependent tau binding proteins, co-
immunoprecipitation assays were carried out using control cortical neuronal cultures 
and treated with 10µM of aggregated Abeta1-42 or 0.25µM of okadaic acid for 3 hours. 
Co-immunoprecipitations were performed using the Tau5 and p-tau Ser262 
antibodies. The immunoprecipitates were sent to Kinexus Company where they were 
subjected to SDS-PAGE and further stained with Coomassie blue (Fig. 19). After 
comparison the results of Tau5 and p-tau Ser262 immunoprecipitations with 
negative control immunoprecipitation we observe bands that specifically appear with 
Tau5 antibody (bands 1-6, Fig. 19) and others with p-tau Ser262 antibody (bands 7-9, 
Fig. 19). These nine bands of interest (1-9; Fig. 19) were excised from the SDS- PAGE 
gel, subjected to trypsin digestion and are now being analyzed by high-resolution 
mass spectrometry for protein identification (Kinexus Company). 
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Figure 19 - Coomassie blue-stained gel of proteins co-immunoprecipitated with Tau5 antibody and p-tau 
Ser262 antibody from rat primary cortical neurons. Rat primary cortical neurons were treated with 10µM of 
Abeta1-42 or 0.25 µM of okadaic acid (OA) for 3 hours. Cleared cell lysates were immunoprecipitated with Tau5 
antibody directed against total tau protein and with p-tau Ser262 antibody directed against phosphorylated tau at 
Ser262 residue and resolved by SDS-PAGE. The gel was stained with Coomassie blue. Molecular masses of protein 
size markers are indicated (KDa). The black boxes indicate the bands of interest excised for enzymatic digestion 
by trypsin and subsequent protein identification by high-resolution mass spectrometry. C, control; IgG, 
immunoglobulins; IP, immunoprecipitation. 
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5. Concluding remarks  
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Abeta effects on tau phosphorylation 
 
In cortex: 
 Total tau levels decreased with prolonged Abeta1-42 exposure; 
 Abeta1-42 (10µM and 20µM) slightly decreased tau phosphorylation at residues 
Ser202 and Thr205, following a 24 hour exposure;  
 Consequently the tau phosphorylation, as a percentage of total tau, at both 
these residues also decreased; 
 In absolute terms tau phosphorylation at residue Ser262 also decreased with 
exposure to higher Abeta1-42 concentrations; 
 Tau phosphorylation at Ser262 increased as a percentage of total tau upon 
exposure to Abeta1-42. 
 
In hippocampus: 
 Total tau levels decreased with Abeta1-42 exposure; 
 Abeta1-42 decreased tau phosphorylation at residues Ser202 and Thr205; 
 Abeta1-42 treatment appeared to provoke a slight increase on tau 
phosphorylation (percentage of total tau) at residues Ser202 and Thr205 upon 
30 minutes of exposure; 
 In absolute terms tau phosphorylation at Ser262 decreased with exposure to 
Abeta1-42; 
 Tau phosphorylation at Ser262 increased as a percentage of total tau after 
prolonged periods of exposure; 
 
 
Protein phosphatases (PPs) involved on tau dephosphorylation 
 
 PP1 is involved in tau dephosphorylation at Ser202 and Thr205 residues; 
 PP2A and PP1 are involved in tau dephosphorylation at Ser262 residue. 
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6. Discussion and Conclusion 
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Tau is a phosphoprotein, which in pathological conditions, such as AD, is found 
hyperphosphorylated. This is turn affects its physiological role due to loss of its 
ability to bind and consequently stabilize the microtubules. Another interesting 
aspect in tau biology is its relationship with Abeta, and has been proposed by amyloid 
hypothesis defenders, that Abeta may induce a series of neuronal signal transduction 
alterations, such as PKs and PPs activation and/or inactivation. As a consequence, tau 
becomes hyperphosphorylated, which in turn promotes disruption of neuronal 
structure and function leading to neuronal death consistent with neurodegeneration. 
Therefore these mechanisms, potentially mediated by Abeta deserve further 
investigation. We addressed the effects of Abeta on tau phosphorylation at Ser202, 
Thr205 and Ser262 residues. The latter are all relevant AD epitopes, since they are 
reported to be hyperphosphorylated in an early stage of AD59-61. In addition, Ser262 
has been proposed to be more injurious than other sites, since it is localized in the 
microtubule-binding domain of tau protein thus decreasing tau biological activity of 
promoting and stabilizing microtubules.  
 
Exposure of primary cultures to Abeta1-42 provoked responses in terms of tau 
phosphorylation, which appear to be consistent with respect to AD pathology. 
Residues phosphorylated in tau include; Ser202, Thr205 (analyzed together) and 
Ser262. The tau phosphorylation profiles for the above mentioned residues were 
quite different upon exposure to Abeta, and further complicated given that it alters 
with respect to the length of time of exposure. Finally, cell type is also relevant, in 
terms of tau phosphorylation levels, as a consequence of exposure to Abeta. Hence, at 
30 min exposure to Abeta1-42, tau phosphorylation remained unchanged except for 
phosphorylation at Ser202 and Thr205 in hippocampal neuronal cultures, which 
increased.  By 3 hours, phosphorylation decreased at these two residues but more so 
for hippocampal neurons (Table 9). Suggesting once again that the latter are probably 
more sensitive to Abeta1-42 or respond more markedly to the latter. The tendency for 
decreased phosphorylation at these two residues, as analyzed together, upon Abeta1-
42 exposure was augmented following the 24 hour exposure period. Thus tau 
phosphorylation at Ser202 and Thr205 decreases upon exposure to Abeta in a 
concentration and time dependent manner and hippocampal neurons appear to 
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respond more readily than cortical neurons (Fig 13 and Fig 15). For this data set, it 
did not go unnoticed that at the 30 minute time point and Abeta1-42 10µM 
concentration there was a slight increase in tau phosphorylation in hippocampal 
neurons, and this deserves to be further addressed. Overall these results are 
discordant to those described by Hu et al. that observed an induced tau 
phosphorylation at Ser202 mediated by Abeta1-42 (10µM) in a time-dependent 
manner in differentiated PC12 cells, with a maximal increase at 24 hours.  One 
possible explanation maybe that a different cell type was used in this study and as 
explained above different responses may occur with respect to cell type. 
 
Tau phosphorylation on Ser262 upon exposure to Abeta resulted in a more 
complex response. At 30 minutes, overall values of absolute tau phosphorylation 
started to decrease and this was clearly evident by 3 hours (Fig. 14 and Fig 16). 
However following 24 hour exposure the percentage of tau phosphorylated at this 
residue increases significantly. Again, hippocampal cultures appear to respond more 
readily. This dual response appears to be related to length of exposure time.  It is 
plausible to hypothesize that at short periods of exposure, physiological mechanisms 
come into play, in order to overcome the effects of exposure to the toxic Abeta 
peptide as described below. However upon longer periods of incubation, intracellular 
regulatory mechanisms ‘break down’ and processes equivalent to a pathological 
situation come into play, resulting in phosphorylation at Ser262. This is consistent 
with tau being hyperphosphorylated in AD. These results are consistent with 
previous observations indicating that Abeta1-42 induces tau phosphorylation at this 
residue in a time-dependent manner, since phosphorylation of tau increases at higher 
periods of exposure86. Interestingly, increased tau phosphorylation induced by 
Abeta1-42 was achieved at Ser262 residue, that plays a critical role in Aβ1-42-induced 
tau toxicity91 since this has a strong effect on microtubules.  
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Table 9 - Summary of results obtained for the tau phosphorylation analyzed following cortical and 
hippocampal neurons exposure to Abeta1-42. Data is based on calculated ratio p-tau/total tau. 
 Tau phosphorylation levels 
 Ser202 and Thr205 Ser262 
Cortical 
neurons 
 
 
- 30 min: no changes; 
- 3 h: slight decrease; 
- 24 h: robust decrease with 
higher Abeta1-42 concentrations. 
 
 
- 30 min: no changes 
- 3 h: decrease with higher 
Abeta1-42 concentration; 
- 24 h: tendency to increase 
with all Abeta1-42 
concentrations. 
 
Hippocampal 
neurons 
 
- 30 min: increase with all Abeta1-
42 concentrations; 
- 3 h: decrease with Abeta1-42 in a 
dose-dependent manner; 
- 24 h: decrease with Abeta1-42 in a 
dose-dependent manner. 
 
 
- 30 min: no changes 
- 3 h: decrease with Abeta1-42 in a 
dose-dependent manner 
- 24 h: increase with all Abeta1-42 
concentrations.  
 
 
 
As already mentioned, in AD tau is aberrantly hyperphosphorylated and 
actually accumulating evidence suggests that PKs and PPs activity are altered in AD 
brain. Therefore it follows that tau hyperphosphorylation is likely to be due to an 
imbalance of PKs and PPs regulation. Many studies have been devoted to elucidating 
the protein kinases involved in tau phosphorylation, however less effort has been 
devoted to elucidating the protein phosphatases involved. Therefore, we went on to 
study the protein phosphatases responsible for tau dephosphorylation at residues 
Ser202, Thr205 and Ser262.  
Our experiments revealed that inhibition of PP1 alone could result in 
increased tau phosphorylation at Ser202 and Thr205. In this way it seems that the 
major PP involved in Ser202 and Thr205 dephosphorylation is PP1, which is 
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consistent with previous observations44. On the contrary Merrick et al. described 
PP2A as being involved in dephosphorylation at these residues92. For tau 
phosphorylation at Ser262, this increased when PP2A and PP1 were inhibited, and 
thus it seems that both are involved in tau dephosphorylation at this residue. Thus 
the major PP that appears to be involved in tau dephosphorylation at Ser262 is PP2A. 
Actually the expression and activity of both these PPs, PP1 and PP2A, are decreased 
in AD brain13, suggesting an involvement of these PPs on tau hyperphosphorylation 
which comprises PHFs of neurofibrillary tangles.  However Liu et al. reported that 
PP1, PP2A and PP2B, all dephosphorylate tau at Ser202, Thr205 and Ser262, but with 
different efficiencies toward different sites and thus further studies to clarify the PPs 
actually involved in tau dephosphorylation are required.  
 
Another important feature of tau metabolism are its binding proteins, and 
actually many proteins have already been found to interact with tau both in vitro and 
in vivo (table 4, section 1.3.3.). The interactome of tau is shaped by its 
phosphorylation and so is crucial to mapping the crosstalk between normal and 
pathologically hyperphosphorylated tau. Therefore our aim is to also identify 
proteins that interact with tau and more specifically assess the role of Ser262 
phosphorylation in shaping this interactome, while also evaluating the Abeta1-42 
effects on this interactome. Our approach was based on co-immunoprecipitation of 
total tau and phosphorylated tau at Ser262, using Tau5 antibody and p-tau ser262 
antibody, respectively, their resolution in SDS-PAGE and then mass spectrometry 
analysis. Hence the immunoprecipitates, which were already subjected to SDS-PAGE 
were stained with Coomassie blue and the bands of interest were excised and are 
now being analyzed by mass spectrometry analysis. A preliminary analysis of the 
SDS-PAGE gel revealed some differences, in terms of band intensity and the 
appearance of novel bands, indicating that probably the phosphorylation at Ser262 
residue modulates the tau interactome. Full identification of these proteins will thus 
be important. 
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In closing, it is evident that tau phosphorylation can be modulated by Abeta. 
This is not a generic response given that different residues exhibit different 
phosphorylation profiles following a period of incubation with Abeta. It is therefore 
reasonable to deduce that the latter is specifically affecting signaling cascades, 
resulting in specific phosphorylation/dephosphorylation signaling events.  Further 
from the work here presented PP1 and PP2A are key protein phosphatases. These 
findings are consistent with previous reports from the laboratory by Vintém et al 
showing that Abeta inhibits PP1. Mechanistically one can propose that Abeta 
production affects PP1 causing its inhibition which in turn favors tau 
hyperphosphorylation. This model is also consistent with the pathological model of 
AD where senile plaques proceed neurofibrillary tangles. Thus these findings deserve 
further investigation and are important in terms of clearly identifying the molecular 
sequential events in Alzheimer’s disease. 
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I. Culture media and Solutions 
 
 
Cell Culture Solutions 
 
 PBS (1x) 
 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
- 8 mM Sodium Phosphate 
- 2 mM Potassium Phosphate 
- 140 mM Sodium Chloride 
- 10 mM Potassim Chloride 
 
Sterilize by filtering through a 0.2 µm filter and store at 4oC. 
 
 10 mg/ml Poly-D-lysine stock (100x) 
 
To a final volume of 10 ml, dissolve in deionised H2O 100 mg of poly-D-lysine (Sigma-
Aldrich). 
 
 Borate buffer 
 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid (Sigma-
Aldrich). Adjust to pH 8.2, sterilize by filtering through a 0.2 µM filter, and store at 
4oC. 
 
 Poly-D-lysine solution 
 
To a final volume of 100 ml, dilute 1 ml of the 10 mg/ml poly-D-lysine stock solution 
in borate buffer. 
 
 
 Hank’s balanced salt solution (HBSS)  
 
This salt solution is prepared with deionised H2O. Final Composition: 
- 137 mM NaCl 
- 5.36 mM KCl 
- 0.44 mM KH2PO4 
- 0.34 mM Na2HPO42H2O 
- 4.16 mM NaHCO3 
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- 5 mM Glucose 
- 1 mM Sodium pyruvate 
- 10 mM HEPES 
 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4oC. 
 
 Complete Neurobasal medium (Cortical primary cultures) 
 
This serum-free medium (Neurobasal; Gibco) is supplemented with: 
 
- 2% B27 supplement (Gibco) 
- 0.5 mM L-glutamine 
- 60 µg/ml Gentamicine (Gibco) 
- 0.001% Phenol Red (Sigma-Aldrich) 
 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4oC. 
 
 Complete Neurobasal medium (Hippocampal primary cultures) 
 
This serum-free medium (Neurobasal; Gibco) is supplemented with: 
 
- 2% B27 supplement (Gibco) 
- 0.5 mM L-glutamine 
- 25 µM L-glutamate (Gibco) 
- 60 µg/ml Gentamicine (Gibco) 
- 0.001% Phenol Red (Sigma-Aldrich) 
 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4oC. 
 
 RIPA buffer 
 
To 6.5 ml of RIPA buffer (Sigma-Aldrich) add: 
 
- 40.3 µL NaF 
- 65 µL NaOrt 
- 65 µL Protease inhibitor cocktail (Sigma-Aldrich) 
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SDS-PAGE and Immunoblotting Solutions 
 
 LGB (Lower gel buffer) (4x) 
 
To 900 ml of deionised H2O add: 
- Tris  181.65 g 
- SDS  4 g 
 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L 
with deionised H2O. 
 
 UGB (Upper gel buffer) (5x) 
 
To 900 ml of deionised H2O add: 
- Tris  75.69 g 
 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1 L 
with deionised H2O. 
 
 30% Acrylamide/0.8% Bisacrylamide 
 
To 70 ml of deionised H2O add: 
- Acrylamide  29.2 g 
- Bisacrylamide  0.8 g 
 
Mix until the solute has dissolved. Adjust the volume to 100 ml with deionised water. 
Filter through a 0.2 µm filter and store at 4oC. 
 
 
 10% APS (ammonium persulfate) 
 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
 
 10% SDS (sodium dodecilsulfate) 
 
In 10 ml of deionised H2O dissolve 1 g of SDS.  
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 Loading Gel Buffer (4x) 
 
- 1 M Tris solution (pH 6.8)  2.5 mL (250 mM) 
- SDS     0.8 g (8%) 
- Glicerol     4 ml (40%) 
- Beta-Mercaptoetanol   2 ml (2%) 
- Bromofenol blue   1 mg (0.01%) 
 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at room 
temperature. 
 
 
 1 M Tris (pH 6.8) solution 
 
To 150 ml of deionised H2O add: 
- Tris base  30.3 g 
 
Adjust the pH to 6.8 and adjust the final volume to 250 ml. 
 
 10x Running Buffer 
 
- Tris  30.3 g (250 mM) 
- Glycine  144.2 g (2.5 M) 
- SDS  10 g (1%) 
 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
 
 
 Resolving (lower) gel solution (for gradient gels, 60 ml) 
 
 5%                  20%      
- H2O 17.4 ml  2.2 ml 
- 30% Acryl/0.8% Bisacryl solution 5 ml  20 ml 
- LGB (4x) 7.5 ml  7.5 ml 
- 10% APS 150 µL  150 µL 
- TEMED 15 µL  15 µL 
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 Stacking (upper) gel solution (20 ml) 
 
 3.5%                 
- H2O 13.2 ml 
- 30% Acryl/0.8% Bisacryl solution 2.4 ml 
- UGB (5x) 4.0 ml 
- 10% APS 200 µL 
- 10% SDS 200 µL 
- TEMED 20 µL 
 
 
 1x Transfer Buffer 
 
- Tris  3.03 g (25 mM) 
- Glycine  14.41 g (192 mM) 
 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 
800 ml with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
 
 
 10x TBS (Tris buffered saline) 
 
- Tris  12.11 g (10 mM) 
- NaCl  87.66 g (150 mM) 
 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O. 
 
 10x TBST (TBS+Tween) 
 
- Tris  12.11 g (10 mM) 
- NaCl  87.66 g (150 mM) 
- Tween 20 5 ml (0.05%) 
 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O. 
 
 
 Membranes Stripping Solution (500 ml) 
 
- Tris-HCl (pH 6.7)  3.76 g (62.5 mM) 
- SDS    10 g (2%) 
- Beta-mercaptoetanol  3.5 ml (100 mM) 
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Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 ml. 
 
 
 
Immunoprecipitation solutions 
 
 Lysis Buffer  
 
- 2M MOPS (pH 7.0)  300 µL (20 mM) 
- 250 mM EGTA   240 µL (2 mM) 
- 250 mM EDTA   600 µL (5 mM) 
- NaF 50 mg/ml   900 µL (30 mM) 
- 100 mM NaOrt   300 µL (1 mM) 
- Triton X-100 100%  300 µL (1%) 
 
 
 Lysis Buffer + Protease Inhibitors (30 ml) 
 
Add to 28819µL of lysis buffer the following quantities for a final volume of 30 mL: 
 
- 100 mM PMSF    300 µL (1 mM) 
- 200 mM Benzamidine   450 µL (3 mM) 
- Pepstatin A 1mg/ml   102 µL (5 µM) 
- Leupeptin 5 mg/ml   28,56 µL (10 µM) 
- 0.1 M Dithiothreitol (DTT)*  300 µL (1mM) 
 
* prepare fresh before use. 
 
 Dithiothreitol (DTT)0.1 M 
 
To 1ml of deionised H2O add 0.0154 g of DTT. 
 
 
 Blocking solution 
 
To 20 ml of PBS 1x add 0.6 g of Bovine Serum Albumine (BSA). 
 
